Vivace Therapeutics scores $30M Series C to take oncology candidate for 'Hippo' pathway to human trial next year

Conner Mitchell

Named for the Italian term indicating a piece of music should be played at an upbeat and lively tempo, California-based Vivace Therapeutics seems to have …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Vivace Therapeutics scores $30M Series C to take oncology candidate for 'Hippo' pathway to human trial next year

Conner Mitchell

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Trump blog: Judge extends nationwide block on NIH payment cuts

RFK Jr. readies review of childhood vaccine schedule after pledging not to

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Vi­vace Ther­a­peu­tics scores $30M Se­ries C to take on­col­o­gy can­di­date for 'Hip­po' path­way to hu­man tri­al next year

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Vivace Therapeutics scores $30M Series C to take oncology candidate for 'Hippo' pathway to human trial next year